Hamadani M. Did brentuximab vedotin’s rise to the top ECHELON of Hodgkin therapeutics invalidate AETHERA results?. haematol [Internet]. 2022Jul.1 [cited 2024Apr.25];107(7):1500-2. Available from: https://haematologica.org/article/view/haematol.2021.280284